Skip to main content

Advertisement

Table 1 The blood pressures, weights, and biochemistry data

From: The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

  WKY (n = 9) SHR (n = 7) EMPA (n = 7) P value (ANOVA)
Body weight (g) 511.2 ± 26.8 452.0 ± 17.3a 420.9 ± 18.4bc < 0.0001
Heart weight (g) 1.92 ± 0.14 2.40 ± 0.43a 2.44 ± 0.26b 0.0029
Systolic pressure (mmHg) 80.7 ± 4.3 114.7 ± 3.8a 83.0 ± 2.7c 0.002
Diastolic pressure (mmHg) 47.0 ± 5.6 87.7 ± 5.3a 45.4 ± 3.6$ 0.002
  1. Data are presented as mean ± standard deviation
  2. With Tukey’s multiple comparison test
  3. aComparisons significant for SHR vs WKY
  4. bComparison significant for EMPA vs WKY
  5. cComparison significant for EMPA vs SHR
  WKY (n = 5) SHR (n = 7) EMPA (n = 7) P value (ANOVA)
Fructosamine (µmol/L) 254.3 ± 66.9 155.2 ± 44.9a 144.6 ± 61.7b 0.0027
BUN (mg/dL) 12.9 ± 1.8 21.8 ± 1.6a 22.5 ± 4.8b 0.0002
Creatinine (mg/dL) 0.56 ± 0.07 0.59 ± 0.10 0.47 ± 0.07c 0.0519
AST (IU/L) 167.3 ± 52.5 190.0 ± 40.6 262.5 ± 138.6 0.1919
ALT (IU/L) 74.3 ± 68.4 174.2 ± 89.0 225.5 ± 194.3 0.1927
Uric acid (mg/dL) 1.79 ± 1.09 2.92 ± 0.82 2.39 ± 1.05 0.1731
Triglyceride (mg/dL) 79.8 ± 9.0 59.4 ± 6.7a 58.4 ± 7.3b 0.0003
Total cholesterol (mg/dL) 120.1 ± 10.0 64.6 ± 6.8a 64.6 ± 23.9b < 0.0001
LDL-C (mg/dL) 33.6 ± 4.9 18.7 ± 4.7a 17.1 ± 7.2b 0.0003
HDL-C (mg/dL) 90.7 ± 7.2 47.5 ± 4.3a 49.2 ± 21.2b < 0.0001
ANP (pg/mL) 82.8 ± 18.6 158.8 ± 69.1 93.8 ± 17.5 0.0659
  1. Data are presented as mean ± standard deviation
  2. With Tukey’s multiple comparison test
  3. aComparisons significant for SHR vs WKY
  4. bComparison significant for EMPA vs WKY
  5. cComparison significant for EMPA vs SHR